As House committees advance bills that would bar American companies from working with some foreign-owned biotechnology companies in the future, industry experts warn ending pharmaceutical relationships with China could lead to drug shortages and supply chain disruptions. Darius Lakdawalla, director of research at University of Southern California Schaeffer Center for Health Policy and Economics, said at the U.S. Pharma and Biotech Summit Thursday (May 16) that cutting ties with foreign companies could worsen supply chain issues in the United States...